Dilated Cardiomyopathy (DCM) Clinical Trials

Find Dilated Cardiomyopathy (DCM) Clinical Trials Near You

The Landscape of T1 Mapping for Disease Profiling in a Real-World Cohort

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are: What are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler native T1 measurement (without contrast dye) instead of the more complex ECV measurement (which requires contrast dye) for diagnosis? Patients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:

• Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines.

• Specific disease categories include:

‣ Cardiomyopathies (HCM, DCM, RCM, ACM)

⁃ Infiltrative disorders (cardiac amyloidosis, Fabry disease)

⁃ Inflammatory conditions (acute/chronic myocarditis)

⁃ Ischemic heart disease (acute/chronic MI)

⁃ Valvular heart disease (aortic stenosis)

⁃ Arrhythmic conditions (atrial fibrillation)

⁃ Metabolic disorders (iron-overload)

⁃ Neoplastic conditions (cardiac tumors)

⁃ Congenital heart disease

⁃ Post-transplant evaluation

• All diagnoses must be confirmed using established guideline-based criteria:

‣ Echocardiographic parameters meeting disease-specific cutoffs

⁃ Cardiac MRI findings consistent with current consensus criteria

⁃ Laboratory biomarkers supporting respective diagnoses

⁃ Histopathological confirmation when clinically indicated

Locations
Other Locations
China
Fuwai Hospital, Chinese Academy of Medical Sciences
RECRUITING
Beijing
Contact Information
Primary
Huaying Zhang, Doctor
zhy_dreamer@163.com
86 13695310578
Time Frame
Start Date: 2020-03-01
Estimated Completion Date: 2026-12-01
Participants
Target number of participants: 2000
Treatments
Healthy Controls
CMR criteria:~Anatomically intact cardiac structures: LVEF, ventricular volumes, and wall thickness within sex- and BSA-adjusted reference ranges (LVEF ≥55%, LVEDVi \<82 mL/m² for females, \<97 mL/m² for males); Absence of pathological tissue characteristics (negative LGE); Normal hemodynamic profile: Competent valvular function without hemodynamically significant regurgitation or stenosis.~Clinical exclusion criteria: No history of coronary artery disease, inflammatory cardiomyopathy, or electrophysiological abnormalities requiring intervention
Myocardial Diseases
Patients with various myocardial diseases including Fabry disease, Iron-overload, atrial fibrillation (AF), hypertension, aortic stenosis (AS), chronic myocardial infarction (MI), acute MI, hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), arrhythmogenic cardiomyopathy (ACM), acute myocarditis, chronic myocarditis, cardiac amyloidosis, cardiac tumor, congenital heart disease, and suspected transplant rejection.
Sponsors
Leads: Chinese Academy of Medical Sciences, Fuwai Hospital

This content was sourced from clinicaltrials.gov